Cellcentric Limited
Research and experimental development on biotechnology · Cambridge
ActiveUnited KingdomIncorporated 2003Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2023-12-31
IXBRL · 133 source facts · 16 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 133 source facts · 16 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 76
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2466_04948632_20231231
- Source archive
- Accounts_Monthly_Data-August2024.zip
Accounts to 2022-12-31
IXBRL · 126 source facts · 16 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 126 source facts · 16 selected values
Not assessed
legacy record
- Reporting period
- 2022-01-01 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 76
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0020_04948632_20221231
- Source archive
- Accounts_Monthly_Data-July2023.zip
Accounts to 2021-12-31
IXBRL · 118 source facts · 10 selected values
Not assessedlegacy record
Accounts to 2021-12-31
IXBRL · 118 source facts · 10 selected values
Not assessed
legacy record
- Reporting period
- 2021-01-01 to 2021-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 48
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0111_04948632_20211231
- Source archive
- Accounts_Monthly_Data-October2022.zip
Accounts to 2020-12-31
IXBRL · 87 source facts · 14 selected values
Not assessedlegacy record
Accounts to 2020-12-31
IXBRL · 87 source facts · 14 selected values
Not assessed
legacy record
- Reporting period
- 2020-06-01 to 2020-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 40
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0094_04948632_20201231
- Source archive
- Accounts_Monthly_Data-September2021.zip
Accounts to 2020-05-31
IXBRL · 87 source facts · 14 selected values
Not assessedlegacy record
Accounts to 2020-05-31
IXBRL · 87 source facts · 14 selected values
Not assessed
legacy record
- Reporting period
- 2019-06-01 to 2020-05-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 40
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0088_04948632_20200531
- Source archive
- Accounts_Monthly_Data-March2021.zip
Registered details
04948632- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2003-10-30
- Jurisdiction
- —
- Registered office
- CHESTERFORD RESEARCH PARK, CAMBRIDGE, CB10 1XL
Classification
1 SIC codes72110
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
8 SH01-derived rounds2026-01-29
£48,379,287 raised
£361,597,937 estimated post-money
2025-04-22
£48,379,287 raised
£303,021,918 estimated post-money
2024-07-11
£49,566,665 raised
£202,749,351 estimated post-money
2023-08-31
£2,356,080 raised
£159,786,201 estimated post-money
2021-10-20
£15,749,119 raised
£126,811,866 estimated post-money
2015-06-18
£309,222 raised
£480,296 estimated post-money
2014-01-31
£21,235,012 raised
£34,154,704 estimated post-money
2013-09-23
£660,466 raised
£10,992,652 estimated post-money
Research and innovation
7 matched grantsEngineering the bone marrow niche to control stem cell regulation, metastatic evolution and cancer dormancyActiveEPSRC · Research Grant · 2024-02-05 – 2029-02-04 · with 22 other participants£6,144,878whole project
Engineering the bone marrow niche to control stem cell regulation, metastatic evolution and cancer dormancyActive
EPSRC · Research Grant · 2024-02-05 – 2029-02-04 · with 22 other participants
£6,144,878
whole project
University of GlasgowleadBayerBeatson West of Scotland Cancer CentreBioascentBlood Cancer UKCardiff UniversityCellCentric LtdCell Guidance Systems LtdCharles River LaboratoriesETH ZurichKartos Therapeutics, Inc.Leukaemia CareLgcLightMachinery IncMainstay MedicalManchester BIOGELNHS Ayrshire & ArranNovartis Pharma AGReprocell-EuropeScreenIn3DSygnature DiscoveryUniversity of Navarra ClinicUniversity of Salamanca
A new application for a novel drug candidate - in lung cancerLead
Innovate UK · Feasibility Studies · 2017-01-01 – 2017-12-31
£126,000
awarded
Characterising and targeting aberrant enhancer function in acute myeloid leukaemia (AML)MRC · Research Grant · 2015-03-29 – 2018-03-28 · with 9 other participants£526,177whole project
Characterising and targeting aberrant enhancer function in acute myeloid leukaemia (AML)
MRC · Research Grant · 2015-03-29 – 2018-03-28 · with 9 other participants
£526,177
whole project
University Of CambridgeleadAstrazenecaBayerCellCentric LtdEuropean Hematology Association (EHA)Medical Research Council (MRC)University of BolognaUniversity Of EdinburghUniversity of SalamancaWellcome Sanger Institute
Novel drug candidates for the treatment of castrate resistant prostate cancerLead
Innovate UK · Collaborative R&D · 2013-06-01 – 2015-09-30
£2,200,000
awarded
New epigenetic reprogramming factors: functional testing in ES and iPS cells and development of small molecule modulatorsBBSRC · Research Grant · 2010-03-01 – 2013-08-30 · with 1 other participant£452,874whole project
New epigenetic reprogramming factors: functional testing in ES and iPS cells and development of small molecule modulators
BBSRC · Research Grant · 2010-03-01 – 2013-08-30 · with 1 other participant
£452,874
whole project
Babraham InstituteleadCellCentric Ltd
Manufacturing Solutions for high value induced Pluripotent Stem cell products (MS-iPS)LeadInnovate UK · Collaborative R&D · 2009-12-01 – 2013-03-31 · with 4 other participants£18,000awarded
Manufacturing Solutions for high value induced Pluripotent Stem cell products (MS-iPS)Lead
Innovate UK · Collaborative R&D · 2009-12-01 – 2013-03-31 · with 4 other participants
£18,000
awarded
CellCentric Limitedlead£18,000
University of Cambridge£0
Nuclear transfer enhancement technology for bio processing and tissue engineeringLeadInnovate UK · Collaborative R&D · 2006-04-01 – 2009-09-30 · with 3 other participants£110,490awarded
Nuclear transfer enhancement technology for bio processing and tissue engineeringLead
Innovate UK · Collaborative R&D · 2006-04-01 – 2009-09-30 · with 3 other participants
£110,490
awarded
University of Nottingham£406,234
University of Cambridge£308,870
CellCentric Limitedlead£110,490
Scaleup signal
OECD growth threshold met
26% employee CAGR